CTLA-4

CTLA-4 (Cytotoxic T-Lymphocyte-Associated Protein 4) is a protein on the surface of certain immune cells that acts as a natural "brake" on the immune system. When CTLA-4 is active, it dampens T-cell responses, which can prevent the body from attacking cancer cells. Drugs that block CTLA-4 release this brake and allow T cells to mount a stronger attack on tumors.

Origin

CTLA-4 was identified in 1987 by French researcher Pierre Golstein and colleagues as a gene expressed in cytotoxic T lymphocytes. Its role as an immune checkpoint was established in the 1990s through work by James Allison, who later shared the 2018 Nobel Prize in Physiology or Medicine for translating this discovery into cancer immunotherapy.

Significance in Asbestos Context

For mesothelioma patients, CTLA-4 is directly relevant because ipilimumab, a CTLA-4-blocking antibody, is part of the FDA-approved combination immunotherapy (ipilimumab plus nivolumab) used as a first-line treatment for unresectable pleural mesothelioma. This combination was approved in 2020 based on the CheckMate 743 trial, which showed improved survival compared to standard chemotherapy, especially for patients with non-epithelioid (sarcomatoid or biphasic) histology. Understanding CTLA-4 helps patients have informed conversations with their oncologists about whether immunotherapy is appropriate, what side effects to watch for, and how their tumor's histologic subtype may influence treatment choice.

Example Sentence

After her biphasic mesothelioma diagnosis, the oncologist recommended a combination of a CTLA-4 inhibitor and a PD-1 inhibitor rather than traditional chemotherapy.

Related Terms

Ipilimumab, Nivolumab, PD-1, Immune Checkpoint Inhibitor, CheckMate 743, Immunotherapy

Notes

• Ask your oncologist whether ipilimumab/nivolumab is appropriate for your case, particularly if your tumor is sarcomatoid or biphasic, where this regimen has shown the strongest benefit.
• CTLA-4 blockade can trigger immune-related side effects affecting the colon, liver, skin, lungs, and endocrine glands; report new symptoms (diarrhea, rash, fatigue, shortness of breath) to your care team immediately rather than waiting for the next appointment.
• Keep copies of pathology reports specifying histologic subtype (epithelioid, sarcomatoid, biphasic). This information drives immunotherapy decisions and is also important documentation for any legal claim.
• If you received immunotherapy, preserve infusion records and billing statements; these treatments are expensive and may be recoverable as damages in an asbestos claim or trust submission.